I have been talking to various audiences over the past five years about the potential of molecular imaging in the care of our patients.

While there has been a movement toward the advocacy of the use of PET imaging for the detection of coronary artery disease (CAD) due to higher resolution and new promising tracers, but whether the modality will trump CT or SPECT as the gold standards remains to be seen.

The ripple effect of the obesity epidemic is felt through the entire healthcare system, and for molecular imaging, it affects safety, efficiency and diagnostic quality.

The practice management considerations, as well as uncertainty about the meaning of a beta-amyloid, scan are impacting early adopters.

Now that the fee-for-service reimbursement model may be coming to an end, radiology providers will have to adjust pracice to survive (and succeed) in a value-based environment.

The first-ever study to analyze 25 years of follow-up data after radiation therapy (RT) treatment for prostate cancer patients has found the treatment controls disease effectively long-term, and if prostate specific antigen (PSA) is less than 0.2 ng/ml at 15 years post-treatment, later recurrence is very unlikely.

Two large cardiology practices in Maine merged with an integrated delivery network. The integration demanded a complete overhaul of governance, IT considerations and molecular imaging workflow.

Recent developments in theranostics could usher in an era that helps drive personalized medicine from research to reality.